Starpharma Holdings Limited (SPHRY)
Develops dendrimer-based medications for bacterial infections, cancer, and antiviral treatments.
$5.30+0.15%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+621.5%
The outlook
SPHRY is trading near its 52-week highs, positioned well above both its 50- and 200-day moving averages. The stock sits at the upper end of its recent range, reflecting sustained upward momentum over the past year. Analyst coverage appears limited; check dedicated financial sites for current ratings and price targets.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range92% of the way from its 52-week low to high
Market cap
$223.1M
52-wk high
$5.70
52-wk low
$0.65
50-day avg
$4.75
200-day avg
$3.48
Trailing P/E
—